Can I Take Vitamin B6 with Testosterone Enanthate?

The direct answer

Testosterone enanthate is a prescription injectable ester of testosterone, marketed as Delatestryl and used for testosterone replacement in men with confirmed hypogonadism. Vitamin B6 (pyridoxine, or its active form pyridoxal-5-phosphate) is a water-soluble B vitamin sold without a prescription. The FDA-approved prescribing information for testosterone enanthate lists interacting drug classes such as anticoagulants, insulin, and corticosteroids; vitamin B6 is not among them, and it does not appear in standard clinical drug-interaction checkers as a testosterone interactant.

That absence of a listed interaction is accurate but incomplete on its own. B6 carries a dose-dependent safety ceiling that has nothing to do with testosterone: sustained high-dose supplementation has been associated with sensory peripheral neuropathy, which is why the NIH Office of Dietary Supplements sets a Tolerable Upper Intake Level of 100 mg/day for adults (NIH ODS Vitamin B6 fact sheet). A person on testosterone enanthate who also takes megadose B6 for another reason is exposed to that same neuropathy risk as anyone else taking that dose. The two issues run in parallel; they do not compound each other through a shared mechanism.

Why the pathways don't intersect

After intramuscular injection, testosterone enanthate is released slowly from an oil depot at the injection site. Plasma esterases cleave the enanthate ester to release free testosterone, which is then aromatized to estradiol, reduced to dihydrotestosterone, and oxidized in the liver largely through CYP3A4, followed by conjugation and renal excretion. A supplement or drug that strongly inhibits or induces CYP3A4, ketoconazole, ritonavir, or rifampin, for example, can meaningfully change testosterone exposure.

Pyridoxine follows an entirely different route: it is phosphorylated in the liver and red blood cells to its active coenzyme form, pyridoxal-5-phosphate, which then participates in amino acid and neurotransmitter metabolism. There is no published pharmacokinetic evidence that B6 or PLP inhibits, induces, or competes with CYP3A4, and no evidence that B6 displaces testosterone from sex hormone-binding globulin or albumin. A displacement interaction of that kind would require structural similarity between the two molecules, which does not exist here.

Laboratory studies have shown that pyridoxal-5-phosphate can interfere with steroid hormone receptor binding at concentrations far above what oral supplementation produces in human plasma. Whether this in vitro finding has any bearing on real-world testosterone activity at supplement doses has not been demonstrated in human trials, and extrapolating from cell-culture concentrations to clinical dosing is not supported by the evidence available. This is a plausible-but-unproven signal, not an established interaction, and it should not be treated as clinical guidance.

What the FDA label actually flags

The FDA label for testosterone enanthate does describe interactions with real clinical consequences:

• Anticoagulants (warfarin): testosterone can potentiate anticoagulant effect, and the label calls for closer INR monitoring.
• Insulin and oral hypoglycemics: testosterone can improve insulin sensitivity, and glucose-lowering medication doses may need downward adjustment.
• Strong CYP3A4 inhibitors or inducers: drugs such as itraconazole or rifampin can raise or lower testosterone exposure.
• Corticosteroids: concurrent use may increase fluid retention through overlapping mineralocorticoid effects.

Vitamin B6 sits in a different category from all of these. It is not listed on the label, and there is no comparable mechanism connecting it to testosterone pharmacology.

The evidence boundary in plain terms

Established: Vitamin B6 has no known pharmacokinetic interaction with testosterone enanthate. The FDA label does not list it as an interacting substance. The NIH Tolerable Upper Intake Level for B6 is 100 mg/day for adults, set because of neuropathy risk at sustained higher intakes, a risk that exists independent of testosterone use.

Plausible but unproven: In vitro data suggest pyridoxal-5-phosphate could interfere with steroid receptor signaling at very high concentrations. Whether this has any measurable effect at supplement doses in humans on TRT has not been studied directly and should not be assumed.

Not established: There is no clinical trial data on B6 supplementation specifically in men on testosterone enanthate. Claims about an exact neuropathy-onset dose beyond the NIH upper limit, or about B6 worsening testosterone-driven changes in red blood cell count, are not supported by controlled human studies and should be treated as unverified until checked against current primary literature.

Requires verification before individualized use: Anyone considering B6 doses above the 100 mg/day upper intake level for a specific reason (for example, historical off-label use for prolactin symptoms) should raise this with the prescribing clinician or pharmacist rather than deciding independently, since dosing decisions depend on the individual's full medication list and lab history.

Evidence-status interaction assessment: B6 and testosterone enanthate

Monitoring that actually matters on testosterone enanthate

Standard TRT monitoring is unaffected by ordinary B6 intake. Clinical practice guidance for testosterone replacement generally calls for checking serum testosterone, hematocrit, and PSA a few months after starting therapy and then periodically thereafter, with therapy held if hematocrit rises to an unsafe level. Adding a standard-dose B6 supplement does not change these intervals.

If someone is taking B6 above the 100 mg/day upper intake level for a specific reason, a periodic plasma pyridoxal-5-phosphate (PLP) level is a reasonable additional check, particularly if any tingling, numbness, or balance change develops. If neuropathy symptoms appear, stopping the B6 and notifying the prescribing clinician is the appropriate first step; testosterone enanthate therapy itself does not need to be interrupted for a B6-related symptom, since the two are mechanistically unrelated.

Situations that call for a closer look

Chronic kidney disease. Pyridoxine handling can be altered in reduced kidney function, and some clinicians limit B6 intake more conservatively in this setting. Anyone with significant CKD on testosterone enanthate who wants to supplement B6 should discuss an appropriate dose with their nephrologist or prescriber rather than following a general supplement label.

Isoniazid or hydralazine use. These medications act as pyridoxine antagonists and can cause B6 deficiency. Someone on one of these drugs who is also on testosterone enanthate may have a genuine medical reason to take supplemental B6, and the dose should be set by the prescribing clinician rather than chosen independently.

Older adults. B6 absorption declines modestly with age, but this does not change the interaction picture with testosterone enanthate. Meeting the standard recommended dietary allowance is a reasonable goal without exceeding the upper intake level.

When to involve a clinician rather than self-manage

Reach out to the prescribing clinician or a pharmacist, rather than adjusting supplements alone, if any of the following apply: B6 intake from all sources (food, multivitamin, and any standalone supplement) is likely to exceed 100 mg/day; new tingling, numbness, or gait changes develop while on B6; hematocrit has been elevated on prior labs; or there is a plan to add a second supplement or medication that also affects nerve function, liver enzymes, or blood counts. None of these require stopping testosterone enanthate on their own, but they do require a conversation before continuing.